 | • レポートコード：GIR-107A11883 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、141ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、選択性Cox-2阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。選択性Cox-2阻害剤の種類別市場規模（メロキシカム、セレコキシブ、エトリコキシブ、イムレコキシブ、エトドラク、パレコキシブ、その他）、用途別市場規模（関節リウマチ、変形性関節症、脊椎症慢性強直性脊椎炎、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・選択性Cox-2阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Boehringer-Ingelheim、TerSera Therapeutics、Iroko Pharmaceuticals、Apotex、Yung Shin Pharmaceutical、Breckenridge Pharmaceutical、Meda Pharmaceuticals、Cipla、Glenmark Pharmaceuticals、Teva、PuraCap Pharmaceutical、Almirall Limited、Lupin Pharmaceuticals、Aurobindo Pharma、Pfizer、Mylan、Takeda、Bayer、Novacap、Abbott、Geri-Care、Perrigo、Kopran、Merck、Hengrui pharmaceutical、Kelun Group、Qilu Pharmaceutical、Taro Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：メロキシカム、セレコキシブ、エトリコキシブ、イムレコキシブ、エトドラク、パレコキシブ、その他 ・用途別分析2016年-2026年：関節リウマチ、変形性関節症、脊椎症慢性強直性脊椎炎、その他 ・選択性Cox-2阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・選択性Cox-2阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・選択性Cox-2阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・選択性Cox-2阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・選択性Cox-2阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Selective Cox-2 Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Selective Cox-2 Inhibitors size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Selective Cox-2 Inhibitors market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Selective Cox-2 Inhibitors market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other
Market segment by Application, can be divided into
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other
Market segment by players, this report covers
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Takeda
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Selective Cox-2 Inhibitors
1.2 Classification of Selective Cox-2 Inhibitors by Type
1.2.1 Overview: Global Selective Cox-2 Inhibitors Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Type in 2020
1.2.3 Meloxicam
1.2.4 Celecoxib
1.2.5 Etoricoxib
1.2.6 Imrecoxib
1.2.7 Etodolac
1.2.8 Parecoxib
1.2.9 Other
1.3 Global Selective Cox-2 Inhibitors Market by Application
1.3.1 Overview: Global Selective Cox-2 Inhibitors Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Rheumatoid Arthritis
1.3.3 Osteoarthritis
1.3.4 Spondylosis Chronica Ankylopoietica
1.3.5 Other
1.4 Global Selective Cox-2 Inhibitors Market Size & Forecast
1.5 Global Selective Cox-2 Inhibitors Market Size and Forecast by Region
1.5.1 Global Selective Cox-2 Inhibitors Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Selective Cox-2 Inhibitors Market Size by Region, (2016-2021)
1.5.3 North America Selective Cox-2 Inhibitors Market Size and Prospect (2016-2026)
1.5.4 Europe Selective Cox-2 Inhibitors Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Selective Cox-2 Inhibitors Market Size and Prospect (2016-2026)
1.5.6 South America Selective Cox-2 Inhibitors Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Selective Cox-2 Inhibitors Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Selective Cox-2 Inhibitors Market Drivers
1.6.2 Selective Cox-2 Inhibitors Market Restraints
1.6.3 Selective Cox-2 Inhibitors Trends Analysis
2 Company Profiles
2.1 Boehringer-Ingelheim
2.1.1 Boehringer-Ingelheim Details
2.1.2 Boehringer-Ingelheim Major Business
2.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product and Solutions
2.1.4 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Boehringer-Ingelheim Recent Developments and Future Plans
2.2 TerSera Therapeutics
2.2.1 TerSera Therapeutics Details
2.2.2 TerSera Therapeutics Major Business
2.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Product and Solutions
2.2.4 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 TerSera Therapeutics Recent Developments and Future Plans
2.3 Iroko Pharmaceuticals
2.3.1 Iroko Pharmaceuticals Details
2.3.2 Iroko Pharmaceuticals Major Business
2.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
2.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Iroko Pharmaceuticals Recent Developments and Future Plans
2.4 Apotex
2.4.1 Apotex Details
2.4.2 Apotex Major Business
2.4.3 Apotex Selective Cox-2 Inhibitors Product and Solutions
2.4.4 Apotex Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Apotex Recent Developments and Future Plans
2.5 Yung Shin Pharmaceutical
2.5.1 Yung Shin Pharmaceutical Details
2.5.2 Yung Shin Pharmaceutical Major Business
2.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
2.5.4 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Yung Shin Pharmaceutical Recent Developments and Future Plans
2.6 Breckenridge Pharmaceutical
2.6.1 Breckenridge Pharmaceutical Details
2.6.2 Breckenridge Pharmaceutical Major Business
2.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
2.6.4 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Breckenridge Pharmaceutical Recent Developments and Future Plans
2.7 Meda Pharmaceuticals
2.7.1 Meda Pharmaceuticals Details
2.7.2 Meda Pharmaceuticals Major Business
2.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
2.7.4 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Meda Pharmaceuticals Recent Developments and Future Plans
2.8 Cipla
2.8.1 Cipla Details
2.8.2 Cipla Major Business
2.8.3 Cipla Selective Cox-2 Inhibitors Product and Solutions
2.8.4 Cipla Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Cipla Recent Developments and Future Plans
2.9 Glenmark Pharmaceuticals
2.9.1 Glenmark Pharmaceuticals Details
2.9.2 Glenmark Pharmaceuticals Major Business
2.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
2.9.4 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Glenmark Pharmaceuticals Recent Developments and Future Plans
2.10 Teva
2.10.1 Teva Details
2.10.2 Teva Major Business
2.10.3 Teva Selective Cox-2 Inhibitors Product and Solutions
2.10.4 Teva Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Teva Recent Developments and Future Plans
2.11 PuraCap Pharmaceutical
2.11.1 PuraCap Pharmaceutical Details
2.11.2 PuraCap Pharmaceutical Major Business
2.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
2.11.4 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 PuraCap Pharmaceutical Recent Developments and Future Plans
2.12 Almirall Limited
2.12.1 Almirall Limited Details
2.12.2 Almirall Limited Major Business
2.12.3 Almirall Limited Selective Cox-2 Inhibitors Product and Solutions
2.12.4 Almirall Limited Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Almirall Limited Recent Developments and Future Plans
2.13 Lupin Pharmaceuticals
2.13.1 Lupin Pharmaceuticals Details
2.13.2 Lupin Pharmaceuticals Major Business
2.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
2.13.4 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Lupin Pharmaceuticals Recent Developments and Future Plans
2.14 Aurobindo Pharma
2.14.1 Aurobindo Pharma Details
2.14.2 Aurobindo Pharma Major Business
2.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Product and Solutions
2.14.4 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Aurobindo Pharma Recent Developments and Future Plans
2.15 Pfizer
2.15.1 Pfizer Details
2.15.2 Pfizer Major Business
2.15.3 Pfizer Selective Cox-2 Inhibitors Product and Solutions
2.15.4 Pfizer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Pfizer Recent Developments and Future Plans
2.16 Mylan
2.16.1 Mylan Details
2.16.2 Mylan Major Business
2.16.3 Mylan Selective Cox-2 Inhibitors Product and Solutions
2.16.4 Mylan Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Mylan Recent Developments and Future Plans
2.17 Takeda
2.17.1 Takeda Details
2.17.2 Takeda Major Business
2.17.3 Takeda Selective Cox-2 Inhibitors Product and Solutions
2.17.4 Takeda Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Takeda Recent Developments and Future Plans
2.18 Bayer
2.18.1 Bayer Details
2.18.2 Bayer Major Business
2.18.3 Bayer Selective Cox-2 Inhibitors Product and Solutions
2.18.4 Bayer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Bayer Recent Developments and Future Plans
2.19 Novacap
2.19.1 Novacap Details
2.19.2 Novacap Major Business
2.19.3 Novacap Selective Cox-2 Inhibitors Product and Solutions
2.19.4 Novacap Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Novacap Recent Developments and Future Plans
2.20 Abbott
2.20.1 Abbott Details
2.20.2 Abbott Major Business
2.20.3 Abbott Selective Cox-2 Inhibitors Product and Solutions
2.20.4 Abbott Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Abbott Recent Developments and Future Plans
2.21 Geri-Care
2.21.1 Geri-Care Details
2.21.2 Geri-Care Major Business
2.21.3 Geri-Care Selective Cox-2 Inhibitors Product and Solutions
2.21.4 Geri-Care Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Geri-Care Recent Developments and Future Plans
2.22 Perrigo
2.22.1 Perrigo Details
2.22.2 Perrigo Major Business
2.22.3 Perrigo Selective Cox-2 Inhibitors Product and Solutions
2.22.4 Perrigo Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Perrigo Recent Developments and Future Plans
2.23 Kopran
2.23.1 Kopran Details
2.23.2 Kopran Major Business
2.23.3 Kopran Selective Cox-2 Inhibitors Product and Solutions
2.23.4 Kopran Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.23.5 Kopran Recent Developments and Future Plans
2.24 Merck
2.24.1 Merck Details
2.24.2 Merck Major Business
2.24.3 Merck Selective Cox-2 Inhibitors Product and Solutions
2.24.4 Merck Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.24.5 Merck Recent Developments and Future Plans
2.25 Hengrui pharmaceutical
2.25.1 Hengrui pharmaceutical Details
2.25.2 Hengrui pharmaceutical Major Business
2.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
2.25.4 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.25.5 Hengrui pharmaceutical Recent Developments and Future Plans
2.26 Kelun Group
2.26.1 Kelun Group Details
2.26.2 Kelun Group Major Business
2.26.3 Kelun Group Selective Cox-2 Inhibitors Product and Solutions
2.26.4 Kelun Group Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.26.5 Kelun Group Recent Developments and Future Plans
2.27 Qilu Pharmaceutical
2.27.1 Qilu Pharmaceutical Details
2.27.2 Qilu Pharmaceutical Major Business
2.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
2.27.4 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.27.5 Qilu Pharmaceutical Recent Developments and Future Plans
2.28 Taro Pharmaceuticals
2.28.1 Taro Pharmaceuticals Details
2.28.2 Taro Pharmaceuticals Major Business
2.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
2.28.4 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019-2021)
2.28.5 Taro Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Selective Cox-2 Inhibitors Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Selective Cox-2 Inhibitors Players Market Share
3.2.2 Top 10 Selective Cox-2 Inhibitors Players Market Share
3.2.3 Market Competition Trend
3.3 Selective Cox-2 Inhibitors Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Selective Cox-2 Inhibitors Revenue and Market Share by Type (2016-2021)
4.2 Global Selective Cox-2 Inhibitors Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2016-2021)
5.2 Selective Cox-2 Inhibitors Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Selective Cox-2 Inhibitors Revenue by Type (2016-2026)
6.2 North America Selective Cox-2 Inhibitors Revenue by Application (2016-2026)
6.3 North America Selective Cox-2 Inhibitors Market Size by Country
6.3.1 North America Selective Cox-2 Inhibitors Revenue by Country (2016-2026)
6.3.2 United States Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
6.3.3 Canada Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
6.3.4 Mexico Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Selective Cox-2 Inhibitors Revenue by Type (2016-2026)
7.2 Europe Selective Cox-2 Inhibitors Revenue by Application (2016-2026)
7.3 Europe Selective Cox-2 Inhibitors Market Size by Country
7.3.1 Europe Selective Cox-2 Inhibitors Revenue by Country (2016-2026)
7.3.2 Germany Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
7.3.3 France Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
7.3.5 Russia Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
7.3.6 Italy Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Type (2016-2026)
8.2 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Application (2016-2026)
8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region
8.3.1 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Region (2016-2026)
8.3.2 China Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
8.3.3 Japan Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
8.3.4 South Korea Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
8.3.5 India Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
8.3.7 Australia Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Selective Cox-2 Inhibitors Revenue by Type (2016-2026)
9.2 South America Selective Cox-2 Inhibitors Revenue by Application (2016-2026)
9.3 South America Selective Cox-2 Inhibitors Market Size by Country
9.3.1 South America Selective Cox-2 Inhibitors Revenue by Country (2016-2026)
9.3.2 Brazil Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
9.3.3 Argentina Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Selective Cox-2 Inhibitors Revenue by Type (2016-2026)
10.2 Middle East & Africa Selective Cox-2 Inhibitors Revenue by Application (2016-2026)
10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country
10.3.1 Middle East & Africa Selective Cox-2 Inhibitors Revenue by Country (2016-2026)
10.3.2 Turkey Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
10.3.4 UAE Selective Cox-2 Inhibitors Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Selective Cox-2 Inhibitors Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Selective Cox-2 Inhibitors Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Selective Cox-2 Inhibitors Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Selective Cox-2 Inhibitors Revenue (USD Million) by Region (2016-2021)
Table 5. Global Selective Cox-2 Inhibitors Revenue Market Share by Region (2021-2026)
Table 6. Boehringer-Ingelheim Corporate Information, Head Office, and Major Competitors
Table 7. Boehringer-Ingelheim Major Business
Table 8. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product and Solutions
Table 9. Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. TerSera Therapeutics Corporate Information, Head Office, and Major Competitors
Table 11. TerSera Therapeutics Major Business
Table 12. TerSera Therapeutics Selective Cox-2 Inhibitors Product and Solutions
Table 13. TerSera Therapeutics Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Iroko Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Iroko Pharmaceuticals Major Business
Table 16. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
Table 17. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Apotex Corporate Information, Head Office, and Major Competitors
Table 19. Apotex Major Business
Table 20. Apotex Selective Cox-2 Inhibitors Product and Solutions
Table 21. Apotex Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Yung Shin Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. Yung Shin Pharmaceutical Major Business
Table 24. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
Table 25. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Breckenridge Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 27. Breckenridge Pharmaceutical Major Business
Table 28. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
Table 29. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Meda Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Meda Pharmaceuticals Major Business
Table 32. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
Table 33. Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Cipla Corporate Information, Head Office, and Major Competitors
Table 35. Cipla Major Business
Table 36. Cipla Selective Cox-2 Inhibitors Product and Solutions
Table 37. Cipla Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 39. Glenmark Pharmaceuticals Major Business
Table 40. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
Table 41. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Teva Corporate Information, Head Office, and Major Competitors
Table 43. Teva Major Business
Table 44. Teva Selective Cox-2 Inhibitors Product and Solutions
Table 45. Teva Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. PuraCap Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 47. PuraCap Pharmaceutical Major Business
Table 48. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
Table 49. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Almirall Limited Corporate Information, Head Office, and Major Competitors
Table 51. Almirall Limited Major Business
Table 52. Almirall Limited Selective Cox-2 Inhibitors Product and Solutions
Table 53. Almirall Limited Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Lupin Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 55. Lupin Pharmaceuticals Major Business
Table 56. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
Table 57. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Aurobindo Pharma Corporate Information, Head Office, and Major Competitors
Table 59. Aurobindo Pharma Major Business
Table 60. Aurobindo Pharma Selective Cox-2 Inhibitors Product and Solutions
Table 61. Aurobindo Pharma Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Pfizer Corporate Information, Head Office, and Major Competitors
Table 63. Pfizer Major Business
Table 64. Pfizer Selective Cox-2 Inhibitors Product and Solutions
Table 65. Pfizer Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Mylan Corporate Information, Head Office, and Major Competitors
Table 67. Mylan Major Business
Table 68. Mylan Selective Cox-2 Inhibitors Product and Solutions
Table 69. Mylan Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Takeda Corporate Information, Head Office, and Major Competitors
Table 71. Takeda Major Business
Table 72. Takeda Selective Cox-2 Inhibitors Product and Solutions
Table 73. Takeda Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Bayer Corporate Information, Head Office, and Major Competitors
Table 75. Bayer Major Business
Table 76. Bayer Selective Cox-2 Inhibitors Product and Solutions
Table 77. Bayer Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Novacap Corporate Information, Head Office, and Major Competitors
Table 79. Novacap Major Business
Table 80. Novacap Selective Cox-2 Inhibitors Product and Solutions
Table 81. Novacap Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Abbott Corporate Information, Head Office, and Major Competitors
Table 83. Abbott Major Business
Table 84. Abbott Selective Cox-2 Inhibitors Product and Solutions
Table 85. Abbott Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Geri-Care Corporate Information, Head Office, and Major Competitors
Table 87. Geri-Care Major Business
Table 88. Geri-Care Selective Cox-2 Inhibitors Product and Solutions
Table 89. Geri-Care Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Perrigo Corporate Information, Head Office, and Major Competitors
Table 91. Perrigo Major Business
Table 92. Perrigo Selective Cox-2 Inhibitors Product and Solutions
Table 93. Perrigo Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Kopran Corporate Information, Head Office, and Major Competitors
Table 95. Kopran Major Business
Table 96. Kopran Selective Cox-2 Inhibitors Product and Solutions
Table 97. Kopran Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 98. Merck Corporate Information, Head Office, and Major Competitors
Table 99. Merck Major Business
Table 100. Merck Selective Cox-2 Inhibitors Product and Solutions
Table 101. Merck Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 102. Hengrui pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 103. Hengrui pharmaceutical Major Business
Table 104. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
Table 105. Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 106. Kelun Group Corporate Information, Head Office, and Major Competitors
Table 107. Kelun Group Major Business
Table 108. Kelun Group Selective Cox-2 Inhibitors Product and Solutions
Table 109. Kelun Group Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 110. Qilu Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 111. Qilu Pharmaceutical Major Business
Table 112. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions
Table 113. Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 114. Taro Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 115. Taro Pharmaceuticals Major Business
Table 116. Taro Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions
Table 117. Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 118. Global Selective Cox-2 Inhibitors Revenue (USD Million) by Players (2019-2021)
Table 119. Global Selective Cox-2 Inhibitors Revenue Share by Players (2019-2021)
Table 120. Breakdown of Selective Cox-2 Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3)
Table 121. Selective Cox-2 Inhibitors Players Head Office, Products and Services Provided
Table 122. Selective Cox-2 Inhibitors Mergers & Acquisitions in the Past Five Years
Table 123. Selective Cox-2 Inhibitors New Entrants and Expansion Plans
Table 124. Global Selective Cox-2 Inhibitors Revenue (USD Million) by Type (2016-2021)
Table 125. Global Selective Cox-2 Inhibitors Revenue Share by Type (2016-2021)
Table 126. Global Selective Cox-2 Inhibitors Revenue Forecast by Type (2021-2026)
Table 127. Global Selective Cox-2 Inhibitors Revenue by Application (2016-2021)
Table 128. Global Selective Cox-2 Inhibitors Revenue Forecast by Application (2021-2026)
Table 129. North America Selective Cox-2 Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 130. North America Selective Cox-2 Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 131. North America Selective Cox-2 Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 132. North America Selective Cox-2 Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 133. North America Selective Cox-2 Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 134. North America Selective Cox-2 Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 135. Europe Selective Cox-2 Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 136. Europe Selective Cox-2 Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 137. Europe Selective Cox-2 Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 138. Europe Selective Cox-2 Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 139. Europe Selective Cox-2 Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 140. Europe Selective Cox-2 Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 141. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 142. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 143. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 144. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 145. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Region (2016-2021) & (USD Million)
Table 146. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 147. South America Selective Cox-2 Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 148. South America Selective Cox-2 Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 149. South America Selective Cox-2 Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 150. South America Selective Cox-2 Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 151. South America Selective Cox-2 Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 152. South America Selective Cox-2 Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 153. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Type (2016-2021) & (USD Million)
Table 154. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 155. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Application (2016-2021) & (USD Million)
Table 156. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 157. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Country (2016-2021) & (USD Million)
Table 158. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Selective Cox-2 Inhibitors Picture
Figure 2. Global Selective Cox-2 Inhibitors Revenue Market Share by Type in 2020
Figure 3. Meloxicam
Figure 4. Celecoxib
Figure 5. Etoricoxib
Figure 6. Imrecoxib
Figure 7. Etodolac
Figure 8. Parecoxib
Figure 9. Other
Figure 10. Selective Cox-2 Inhibitors Revenue Market Share by Application in 2020
Figure 11. Rheumatoid Arthritis Picture
Figure 12. Osteoarthritis Picture
Figure 13. Spondylosis Chronica Ankylopoietica Picture
Figure 14. Other Picture
Figure 15. Global Selective Cox-2 Inhibitors Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global Selective Cox-2 Inhibitors Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global Selective Cox-2 Inhibitors Revenue Market Share by Region (2016-2026)
Figure 18. Global Selective Cox-2 Inhibitors Revenue Market Share by Region in 2020
Figure 19. North America Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Selective Cox-2 Inhibitors Market Drivers
Figure 25. Selective Cox-2 Inhibitors Market Restraints
Figure 26. Selective Cox-2 Inhibitors Market Trends
Figure 27. Boehringer-Ingelheim Recent Developments and Future Plans
Figure 28. TerSera Therapeutics Recent Developments and Future Plans
Figure 29. Iroko Pharmaceuticals Recent Developments and Future Plans
Figure 30. Apotex Recent Developments and Future Plans
Figure 31. Yung Shin Pharmaceutical Recent Developments and Future Plans
Figure 32. Breckenridge Pharmaceutical Recent Developments and Future Plans
Figure 33. Meda Pharmaceuticals Recent Developments and Future Plans
Figure 34. Cipla Recent Developments and Future Plans
Figure 35. Glenmark Pharmaceuticals Recent Developments and Future Plans
Figure 36. Teva Recent Developments and Future Plans
Figure 37. PuraCap Pharmaceutical Recent Developments and Future Plans
Figure 38. Almirall Limited Recent Developments and Future Plans
Figure 39. Lupin Pharmaceuticals Recent Developments and Future Plans
Figure 40. Aurobindo Pharma Recent Developments and Future Plans
Figure 41. Pfizer Recent Developments and Future Plans
Figure 42. Mylan Recent Developments and Future Plans
Figure 43. Takeda Recent Developments and Future Plans
Figure 44. Bayer Recent Developments and Future Plans
Figure 45. Novacap Recent Developments and Future Plans
Figure 46. Abbott Recent Developments and Future Plans
Figure 47. Geri-Care Recent Developments and Future Plans
Figure 48. Perrigo Recent Developments and Future Plans
Figure 49. Kopran Recent Developments and Future Plans
Figure 50. Merck Recent Developments and Future Plans
Figure 51. Hengrui pharmaceutical Recent Developments and Future Plans
Figure 52. Kelun Group Recent Developments and Future Plans
Figure 53. Qilu Pharmaceutical Recent Developments and Future Plans
Figure 54. Taro Pharmaceuticals Recent Developments and Future Plans
Figure 55. Global Selective Cox-2 Inhibitors Revenue Share by Players in 2020
Figure 56. Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 57. Global Top 3 Players Selective Cox-2 Inhibitors Revenue Market Share in 2020
Figure 58. Global Top 10 Players Selective Cox-2 Inhibitors Revenue Market Share in 2020
Figure 59. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 60. Global Selective Cox-2 Inhibitors Revenue Share by Type in 2020
Figure 61. Global Selective Cox-2 Inhibitors Market Share Forecast by Type (2021-2026)
Figure 62. Global Selective Cox-2 Inhibitors Revenue Share by Application in 2020
Figure 63. Global Selective Cox-2 Inhibitors Market Share Forecast by Application (2021-2026)
Figure 64. North America Selective Cox-2 Inhibitors Sales Market Share by Type (2016-2026)
Figure 65. North America Selective Cox-2 Inhibitors Sales Market Share by Application (2016-2026)
Figure 66. North America Selective Cox-2 Inhibitors Revenue Market Share by Country (2016-2026)
Figure 67. United States Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Canada Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Mexico Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Europe Selective Cox-2 Inhibitors Sales Market Share by Type (2016-2026)
Figure 71. Europe Selective Cox-2 Inhibitors Sales Market Share by Application (2016-2026)
Figure 72. Europe Selective Cox-2 Inhibitors Revenue Market Share by Country (2016-2026)
Figure 73. Germany Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. France Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. United Kingdom Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Russia Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Italy Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Asia-Pacific Selective Cox-2 Inhibitors Sales Market Share by Type (2016-2026)
Figure 79. Asia-Pacific Selective Cox-2 Inhibitors Sales Market Share by Application (2016-2026)
Figure 80. Asia-Pacific Selective Cox-2 Inhibitors Revenue Market Share by Region (2016-2026)
Figure 81. China Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Japan Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. South Korea Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. India Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Southeast Asia Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Australia Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. South America Selective Cox-2 Inhibitors Sales Market Share by Type (2016-2026)
Figure 88. South America Selective Cox-2 Inhibitors Sales Market Share by Application (2016-2026)
Figure 89. South America Selective Cox-2 Inhibitors Revenue Market Share by Country (2016-2026)
Figure 90. Brazil Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 91. Argentina Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 92. Middle East and Africa Selective Cox-2 Inhibitors Sales Market Share by Type (2016-2026)
Figure 93. Middle East and Africa Selective Cox-2 Inhibitors Sales Market Share by Application (2016-2026)
Figure 94. Middle East and Africa Selective Cox-2 Inhibitors Revenue Market Share by Country (2016-2026)
Figure 95. Turkey Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 96. Saudi Arabia Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 97. UAE Selective Cox-2 Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 98. Methodology
Figure 99. Research Process and Data Source
世界のCox-2阻害剤市場予測（～2024年） Cox-2 Inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, Cox-2, an enzyme responsible for inflammation and pain. These drugs are responsible for decreasing the production of prostaglandins. Scope of the Report: The global Cox-2 Inhibitors mar…- 世界の波長選択スイッチ市場 2021：企業別、地域別、種類・用途別 The Wavelength Selective Switch market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- 世界のNSCLC用標的薬HER2阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug HER2 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場 2021：企業別、地域別、種類・用途別 The PARP (Poly ADP-ribose Polymerase) Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimi…
- 世界のNSCLC用標的薬ROS1阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug ROS1 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…